Dealings in Securities by an Executive Director and Executive Officers of AngloGold Ashanti plc
Name of Executive Director
Gillian Doran
Name of Company
AngloGold Ashanti plc
Date of transaction
15 May 2025
Nature of transaction
Off-market receipt of vested shares under the 2023 Deferred Share Plans (DSP)
Class of security
Ordinary shares
Number of securities
22,325
Price per security
Nil
Nature and extent of interest
Direct, Beneficial
Name of Executive Director
Gillian Doran
Name of Company
AngloGold Ashanti plc
Date of transaction
15 May 2025
Nature of transaction
On-market sale of shares to fund tax liability in relation to DSP awards
Class of security
Ordinary shares
Number of securities sold
8,260
Price per security
US$40.37581
Value of transaction (excluding fees)
US$333,504.21
Nature and extent of interest
Direct, Beneficial
(1)
Weighted average price. These shares were sold in multiple transactions at prices ranging from US$40.3737 to US$40.3783 inclusive.
Name of Executive Officer
Terry Briggs
Name of Company
AngloGold Ashanti plc
Date of transaction
15 May 2025
Nature of transaction
Off-market receipt of vested shares under the 2023 Deferred Share Plans (DSP)
Class of security
Ordinary shares
Number of securities
25,514
Price per security
Nil
Nature and extent of interest
Direct, Beneficial
Name of Executive Officer
Terry Briggs
Name of Company
AngloGold Ashanti plc
Date of transaction
15 May 2025
Nature of transaction
On-market sale of vested DSP awards
Class of security
Ordinary shares
Number of securities sold
9,440
Price per security
US$40.39371
Value of transaction (excluding fees)
US$381,316.55
Nature and extent of interest
Direct, Beneficial
(1)
Weighted average price. These shares were sold in multiple transactions at prices ranging from US$40.3755 to US$40.4001 inclusive.
Name of Executive Officer
Marcelo Godoy
Name of Company
AngloGold Ashanti plc
Date of transaction
15 May 2025
Nature of transaction
Off-market receipt of vested shares under the 2023 Deferred Share Plans (DSP)
Class of security
Ordinary shares
Number of securities
25,745
Price per security
Nil
Nature and extent of interest
Direct, Beneficial
Name of Executive Officer
Marcelo Godoy
Name of Company
AngloGold Ashanti plc
Date of transaction
15 May 2025
Nature of transaction
On-market sale of vested DSP awards
Class of security
Ordinary shares
Number of securities sold
9,526
Price per security
US$40.37501
Value of transaction (excluding fees)
US$384,612.69
Nature and extent of interest
Direct, Beneficial
(1)
Weighted average price. These shares were sold in multiple transactions at prices ranging from US$40.3627 to US$40.4104 inclusive.
JSE Sponsor: The Standard Bank of South Africa Limited
View source version on businesswire.com: https://www.businesswire.com/news/home/20250516790861/en/
Contacts
Media Andrea Maxey+61 8 9425 4603 / +61 400 072 199amaxey@aga.gold
General inquiriesmedia@anglogoldashanti.com
Investors Andrea Maxey+61 8 9425 4603 / +61 400 072 199amaxey@aga.gold
Yatish Chowthee+27 11 637 6273 / +27 78 364 2080yrchowthee@aga.gold
Website: www.anglogoldashanti.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
31 minutes ago
- Yahoo
GE HealthCare Technologies Second Quarter 2025 Earnings: EPS Beats Expectations
GE HealthCare Technologies (NASDAQ:GEHC) Second Quarter 2025 Results Key Financial Results Revenue: US$5.01b (up 3.5% from 2Q 2024). Net income: US$486.0m (up 14% from 2Q 2024). Profit margin: 9.7% (in line with 2Q 2024). EPS: US$1.06 (up from US$0.94 in 2Q 2024). We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. All figures shown in the chart above are for the trailing 12 month (TTM) period GE HealthCare Technologies EPS Beats Expectations Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 19%. Looking ahead, revenue is forecast to grow 4.1% p.a. on average during the next 3 years, compared to a 8.2% growth forecast for the Medical Equipment industry in the US. Performance of the American Medical Equipment industry. The company's shares are down 10.0% from a week ago. Valuation Our analysis of these results suggests GE HealthCare Technologies may be undervalued based on 6 important criteria we look at. To explore our complete evaluation click here and get an understanding of what analysts are thinking about the company's future. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Forbes
an hour ago
- Forbes
Apple's $275 Billion China Bet Is Now A Major Risk
Apple sells more than 220 million iPhones a year. By most estimates, nine in ten are made in China. Many of the components in Apple products are made, sourced, and assembled in China. The tech giant reported robust earnings for the three months to June, but the future is cloudy. It has been for some time because of Apple's reliance on China and the increasing tension between China and the US. Tariffs are one manifestation of the growing geopolitical strife. Chief executive Tim Cook told analysts on a conference call that tariffs had already cost Apple $800 million in the previous quarter, and may add $1.1bn in costs to the next quarter. But it is not just the costs that tariffs will add to the Apple supply chain. Apple has nurtured Chinese companies whose products are now highly competitive with the tech giant. In the book Apple in China, the author Patrick McGee reports that Apple pledged in 2016 that over the following five years, it would invest more than $275 billion in China. That pledge was exceeded. The sophisticated supply chain Apple built in the country, with suppliers that Apple nurtured, is now being leveraged by Chinese companies, notably Huawei, to build sophisticated electronics products. Huawei's Mate XT is a more expensive phone with alluring features than the iPhone. Apple isn't expected to match these product capabilities until 2017. Apple has gone from leadership in design in this market, with the margins to match, to having serious competition. How could Apple have been so stupid? A fundamental concept of risk management is that you don't put all your eggs in one basket. Patrick McGee explains how this came to be in his outstanding book. McGee interviewed over 200 people, mostly Apple employees, to provide insights on this 'famously secretive company.' Apple's Historic Supply Chain Historically, Apple manufactured its own products across several regions. In 1983, Apple opened a highly automated plant in Fremont, California, to produce the first Macintosh computers. Apple established a presence in Europe with a plant in Cork, Ireland. This plant, which opened in 1980, later manufactured customized Macintosh computers for European markets. This is the historic way of hedging your bets and managing risk. Apple understood this principle. But as contract manufacturing emerged as an alternative to a company owning its own manufacturing plants, Apple experimented with this model and achieved positive outcomes. The theory behind contract manufacturing is that companies should focus on what they do best, their core competencies. In Apple's case, that was design. Initially, they were working with American firms and had plants in the US. But Taiwanese headquartered Foxconn proved to have better capabilities than its US rivals, and Foxconn won an increasing share of Apple's final assembly business. You can still practice effective risk management using contract manufacturers with plants in different regions of the world. Foxconn, at Apple's behest, did experiment with manufacturing in other regions of the world in addition to China. But Foxconn, a tremendously harsh taskmaster when it comes to their labor force, struggled to achieve the same level of quality, cost, and scalability anywhere but in their facilities in mainland China. Foxconn then committed to relying on production based in China. As Foxconn delivered better results than its competitors, they gained a larger and larger share of Apple's business. Apple's Strategy in Procurement Apple does not believe in win/win procurement or vested outsourcing. McGee points out that the iPhone accounts for fewer than 20% of smartphones sold globally, yet it garners more than 80% of industry profits. 'In no other market does a minority player command this kind of dominance.' 'Insofar as this statistic was discussed at all, it was chalked up to Apple's brand appeal.' This is not entirely true, says McGee. Apple was able to get suppliers to work for a pittance. As the design leader, suppliers came to believe that other electronics OEMs would copy the cutting-edge features in Apple phones and that they would be the leading contenders to win deals with Apple's competitors. These deals would command much higher margins. The Taiwanese contract manufacturer Foxconn was the first to come to this conclusion. They bet big on this model. And they grew to be the world's largest contract manufacturer based on this bet. A Different Approach to Contract Manufacturing Companies can differentiate their products in different ways. Differentiation can be based on price, a broad set of product choices, service, or market-leading product capabilities. Being on the cutting edge of design is how Apple has always differentiated itself. This led to a fundamentally different kind of supply chain for Apple. Apple's electronics rivals sell a limited number of units across dozens of different models per year. The follow-the-leader strategy employed by these companies was based on using standardized parts with wider tolerances. 'But Apple was different,' McGee wrote. 'Apple's product portfolio remained radically simplified. Even by 2015, Apple was only releasing two new iPhones a year. They were hand crafting luxury phones but doing it in mass market quantities. In their search for suppliers, Apple gravitated toward quality, not price. To reach that quality, Apple had to come up with new processes to make the phones; but until Apple chose a new design these processes wouldn't exist. So it had to work far more intimately with suppliers.' This supplier intimacy model included designing and purchasing the equipment that the suppliers used. This is very different from standard contract manufacturing, where the contract manufacturer purports to have better manufacturing capabilities than the companies they work for, and their clients take a hands-off approach to managing production. 'Apple took extraordinary control over its suppliers to ensure it was getting the appropriate prices,' McGee explained. 'It demanded access to every detail about the suppliers' operating costs, from the wages of its workers and the cost of its dormitories to the bill of materials and expense of the machinery.' Apple also procured components on behalf of the suppliers. 'In fact, Apple often had a better sense of the supplier's operation costs than the supplier itself.' And as Foxconn concentrated on manufacturing in China, an industrial cluster of suppliers would grow up around these plants. Apple engineers would teach these suppliers, competing suppliers for different components, how to do quality manufacturing on a huge scale. China Subsidized Manufacturing in China Foxconn concentrated on manufacturing in China not just because of the low wages of the Chinese workers, but because the state subsidized and promoted export-led production in numerous ways. If you want to build a new factory in the US or Europe, obtaining the necessary building permits and complying with other regulations can take years. In China, authorities could make this happen in months. China would give Foxconn and some of the suppliers the land on which the factories would be built and then build the road infrastructure at no cost to Foxconn or their suppliers. Initially, China even bought new machine tools for companies like Foxconn. Local regions often lacked the necessary workers. China facilitated getting these workers from other, poorer regions of the nation. Are there rules about the number of hours workers are allowed to work, overtime, or environmental compliance? China prioritized building a sophisticated manufacturing base over the enforcement of these pesky regulations. Apple Has Been Captured by China McGee concludes that for Apple to extricate itself from production in China will be tremendously difficult. Suppliers with the requisite skills don't exist in other regions, and there is no guarantee that China will permit its indigenous suppliers to produce outside the country. The Chinese government can also make diversification painful. Beijing has deployed a number of tactics against other companies to make this point. Electricity suddenly becomes available for only a few hours a day. Raw materials can be stopped before they arrive at the factory. McGee concludes that there is no way Apple could diversify from China in any meaningful way within the next five years. 'It's just impossible.'
Yahoo
an hour ago
- Yahoo
UnitedHealth Group Announces Changes to Leadership Team
July 31, 2025--(BUSINESS WIRE)--UnitedHealth Group (NYSE: UNH) today announced Wayne S. DeVeydt has been appointed its chief financial officer, effective September 2, 2025. John F. Rex, who joined the company in 2012 and has been CFO since 2016, will become strategic advisor to the CEO on the same date. "Wayne DeVeydt combines deep financial acumen and operating experience with the mission-oriented and compassionate approach to health care that is a perfect fit for UnitedHealth Group," said Stephen J. Hemsley, company chairman and chief executive officer. "John Rex has been an exceptional leader, having helped guide our company through substantial change with both strategic vision and strong commitment to our mission," said Hemsley. "I look forward to his continued insights as UnitedHealth Group moves forward." DeVeydt, 55, most recently has been a managing director and operating partner at Bain Capital, working with client leaders on operational improvement and growth acceleration. From 2018-2020, he was chairman and CEO of Surgery Partners, Inc. in Nashville, expanding the operational scale and financial performance of the surgical services firm. He joined Anthem, Inc. (now Elevance) in 2005 and served as its chief financial officer from 2007 to 2016. Prior to joining Anthem, DeVeydt served as a partner with PricewaterhouseCoopers LLP, with a focus on the health care sector. "There is no organization besides UnitedHealth Group that presents the kinds of opportunities to make a difference in health care, from individual patient care to broad system efficiency, so I am eagerly looking forward to joining the team," said DeVeydt. "I've been fortunate to know John Rex for over two decades and am honored to follow a leader of his caliber." Rex, 63, joined UnitedHealth Group as chief financial officer of the company's then newly established Optum business and previously had spent his career focused in health care across multiple roles and sectors. "This pivotal moment for UnitedHealth Group is the right time for a new yet greatly experienced executive like Wayne DeVeydt, and I look forward to supporting him and the entire leadership team while continuing to advise on a range of matters," said Rex. About UnitedHealth Group UnitedHealth Group is a health care and well-being company with a mission to help people live healthier lives and help make the health system work better for everyone through two distinct and complementary businesses. Optum delivers care aided by technology and data, empowering people, partners and providers with the guidance and tools they need to achieve better health. UnitedHealthcare offers a full range of health benefits, enabling affordable coverage, simplifying the health care experience and delivering access to high-quality care. Visit UnitedHealth Group at and follow UnitedHealth Group on LinkedIn. View source version on Contacts Media: uhgmedia@ UnitedHealth Group Media Sign in to access your portfolio
